Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06592586
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-09
Brief Title:
A Follow-up Trial of GBS-NNNN2 Vaccine in Healthy Pregnant Women
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Follow-up Trial to Assess the Persistence of the Immune Response to the Group B Streptococcus Vaccine GBS-NNNN2 After a Primary Vaccination of Healthy Pregnant Women and to Assess Safety Reactogenicity and Immunogenicity of the GBS-NNNN2 Vaccine When Administered During Follow-Up As a Booster Dose During a New Pregnancy
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main objective of the study is to evaluate the persistence of the immunoglobulin G IgG antibody responses specific to Alpha-like protein CN AlpCN Ribosomal Protein N RibN Alpha-like protein 1N Alp1N and Alpha-like protein 2 and 3 Alp2-3N after a primary vaccination with GBS-NNNN2 in all participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None